Jump to content
World's Largest Herpes Support Group
Sign in to follow this  
accelerate the response

Peregrine/Bavituximab

Recommended Posts

accelerate the response

Anyone from HCS live in California and able to go to this conference? It seems to me that Peregrine are ramping up the news flow all the time about bavituximab.

Peregrine Pharmaceuticals to Present at Roth Capital Partners OC Growth Stock Conference

TUSTIN, CA -- (MARKET WIRE) -- 03/10/11 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced it will present at the ROTH Capital Partners 23rd Annual OC Growth Stock Conference in Laguna Niguel, California on Monday, March 14, 2011 at 2:00 p.m. Pacific Time (5:00 p.m. ET).

Peregrine's presentation will be webcast live and available for replay at: http://ir.peregrineinc.com/events.cfm

For more information about this conference, please visit: http://www.roth.com/main/page.aspx?PageID=7236

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing multiple clinical programs in cancer and hepatitis C virus infection with its lead product candidate bavituximab and novel brain cancer agent Cotara®. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.

Add to Digg Bookmark with del.icio.us Add to Newsvine

Share this post


Link to post
Share on other sites
helpiamconfused2
Anyone from HCS live in California and able to go to this conference? It seems to me that Peregrine are ramping up the news flow all the time about bavituximab.

Peregrine Pharmaceuticals to Present at Roth Capital Partners OC Growth Stock Conference

TUSTIN, CA -- (MARKET WIRE) -- 03/10/11 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced it will present at the ROTH Capital Partners 23rd Annual OC Growth Stock Conference in Laguna Niguel, California on Monday, March 14, 2011 at 2:00 p.m. Pacific Time (5:00 p.m. ET).

Peregrine's presentation will be webcast live and available for replay at: http://ir.peregrineinc.com/events.cfm

For more information about this conference, please visit: http://www.roth.com/main/page.aspx?PageID=7236

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing multiple clinical programs in cancer and hepatitis C virus infection with its lead product candidate bavituximab and novel brain cancer agent Cotara®. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.

Add to Digg Bookmark with del.icio.us Add to Newsvine

We'll all be able to listen to it by logging in here, on or after March 14, 5P EST.

Peregrine's presentation will be webcast live and available for replay at: http://ir.peregrineinc.com/events.cfm

Share this post


Link to post
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now
Sign in to follow this  

Advertisement

Try a Lysine supplement for cold sores

  • The Hive is Thriving!

    • Total Topics
      68,798
    • Total Posts
      460,031
  • Posts

    • Miss Horne
      There’s new treatment available for cmv and shingles but nothing yet for hsv. It’s like a slap in the face! 
    • Miss Horne
      Any ladies out there suffered with this? There seems to be little information about it on the net. Thanks in advance. 
    • Roja
      Rejection will be there during your whole life. But not because of herpes, also because of how you are, at work, at your private life. It's just a part of life! Just have in mind that if people reject you because of stupid little things like herpes, they are not even worth continuing as a part of your life.  I think the best way of fighting the stigma is to be 100% convinced that there is NO NEED to feel ashamed, bad, disgusting because of herpes. I one day understood some very important thing: I did NOTHING differently than my friends who don't have herpes. I had sex (they did), sometimes with protection (they did), sometimes without (they did). I had ONS (they did), I had long term relationships (they did), I received wonderful and less wonderful oral sex, haha (they did). The only difference is that I got genital herpes from someone who didn't even know. So why exactly should I feel disgusting or bad?  And also: Know the facts. That is the safest way to destroy stigma in my opinion. If someone tells you: "Yuck! Herpes is disgusting!" you can answer: "I don't think that 80 % of the world population are disgusting because they have a virus in their bodies."  I also recommend this video from "Laureen". She has really great videos about herpes!       
    • Miss Horne
      Thanks for the comments. Looks like the only think that might have a shot at helping us in the future is the drug Pritlevir then. 
    • WilsoInAus
      @PeaceNeeded no there is zero relationship between penile spines and HSV-2, no such variant is possible.
×

Important Information

We have placed cookies on your device to help make this website better. You can adjust your cookie settings, otherwise we'll assume you're okay to continue.